Our products




Reference product


Polymorphic form

Therapeutic Area

Cardiovascular system



EU DMF readiness

Drug description:

Acenocumarol is a coumarin derivative acts as an anticoagulant agent. It is used for the treatment of atrial fibrillation, atrial flutter, atrial tachycardia, deep vein thrombosis, dyskinesia, left ventricular dysfunction, myocardial infarction, pulmonary embolism, thromboembolic disease.
It is formulated as tablets for oral route of administration.

Mechanism of action:

Acenocumarol is a vitamin K antagonist; inhibits vitamin K epoxide reductase, thereby inhibiting the reduction of vitamin K and the availability of vitamin KH2. This prevents gamma carboxylation of glutamic acid residues near the N-terminals of the vitamin K-dependent clotting factors, including factor II, VII, IX, and X and anticoagulant proteins C and S. This prevents their activity and thus thrombin formation.

Products protected by valid patents are not offered for commercial sale in countries where the sale of such products constitutes patent infringement but are offered solely for uses reasonably related to the development and submission of information under a law regulating the manufacture, use or sale of drugs. It is within the buyer’s responsibility and liability to check the patent situation of the product in the imported market(s).
Polpharma’s strategic investment in HPAPI facility
We have launched an investment in a specialized facility
for the R&D and Production of highly active substances
with an OEL value of 10 ng/m3 (OEB 6).

The HP API investment includes separate process
laboratories (PDL), analytical laboratories (ADL)
with the possibility of performing Quality Control
analyses, and a GMP kilo-lab production line with
volume up to 1.5 kg with potential volume increase.